IgE-based Immunotherapy of Cancer -A Comparative Oncology ApproachJosef Singer1 and Erika Jensen-Jarolim1,2*
- *Corresponding Author:
- Prof. Dr. Erika Jensen-Jarolim
Comparative Immunology and Oncology
Institute of Pathophysiology and Allergy Research
Medical University of Vienna
Waehringer Guertel 18-20, A-1090 Vienna, Austria
E-mail: [email protected]
Received date: May 03, 2014; Accepted date: May 27, 2014; Published date: May 31, 2014
Citation: Singer J, Jarolim EJ (2014) IgE-based Immunotherapy of Cancer -A Comparative Oncology Approach. J Carcinog & Mutagen 5:176. doi: 10.4172/2157-2518.1000176
Copyright: © 2014 Josef S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Antibody-based immunotherapies are important therapy options in human oncology. Although human humoral specific immunity is constituted of five different immunoglobulin classes, currently only IgG-based immunotherapies have proceeded to clinical application. This review, however, discusses the benefits and difficulties of IgE-based immunotherapy of cancer, with special emphasis on how to translate promising preclinical results into clinical studies. Pursuing the “Comparative Oncology” approach, novel drug candidates are investigated in clinical trials with veterinary cancer patients, most often dogs. By this strategy drug development could be speeded up, animal experiments could be reduced and novel therapy options could be introduced benefitting humans as well as man’s best friend.